Research Paper Volume 12, Issue 18 pp 18297—18321

Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients

Figure 6. Predictions of the immunotherapy response in GBM patients. The violin plots present the expression of 6 principal immune checkpoint molecules, namely, PDCD1 (PD1), CD274 (PDL1), PDCD1LG2 (PDL2), CTLA4, CD80, and CD86, in scRNA-seq data (A) and bulk RNA-seq data, including the TCGA (B) and CGGA cohorts (C). Subclass mapping analysis was used to predict the likelihood of the clinical response to anti-PD1 and anti-CTLA4 therapy for MC1 and MC2 GBM patients from the TCGA (D) and CGGA (E) cohorts. R represents immunotherapy responders, while noR represents immunotherapy nonresponders. A Bonferroni-corrected P value < 0.05 was considered statistically significant.